NASDAQ:NITE - Nightstar Therapeutics plc
$25.51
 $0.01
+0.04%
4:00PM EDT
2019-04-18
Nightstar Therapeutics PLC, formerly Nightstar Therapeutics Limited, is a clinical-stage gene therapy company. The Company is focused on developing and commercializing novel one-time treatments for patients suffering from rare inherited retinal diseases that would otherwise progress to blindness. The Company is developing a pipeline of proprietary product candidates that are designed to substantially modify or halt the progression of inherited retinal diseases. The Companys lead product candidate, NSR-REP1, for the treatment of choroideremia, or CHM, is entering Phase III clinical development. The Company is also conducting a Phase I/II clinical trial with its second product candidate, NSR-RPGR, for the treatment of X-linked retinitis pigmentosa, or XLRP. The Companys third product candidate, NSR-BEST1, is in preclinical development for the treatment of Best vitelliform macular dystrophy, or Best disease.The Companys NSR-REP1 is comprised of an AAV2 vector containing recombinant human complementary DNA, or cDNA, which is designed to produce REP1 inside the eye. NSR-REP1 is comprised of a standard AAV vector combined with the human REP1 cDNA and a woodchuck hepatitis post-transcriptional regulatory element, or WPRE, sequence. Read more at  reuters.com
sector:  health care
industry:  biotechnology
the data below are updated and published after 9pm EDT each trading day
  NITE     avg for
industry  
  avg for
sector  
42 stocks weight:  0. 48   203. 85   241. 91  
42 stocks rank:  3. 85 K 1. 44 K 1. 05 K
# analyst opinions:  9. 00   14. 51   13. 97  
mean recommendation:  2. 70   2. 09   2. 01  

quick ratio:  12. 08   5. 27   1. 81  
current ratio:  12. 45   5. 62   2. 25  

target price low:  25. 50   84. 80   115. 21  
target price avg:  26. 06   111. 51   137. 51  
target price high:  30. 00   135. 81   157. 84  
1-yr high:  27. 78   114. 23   138. 78  
last close:  25. 51   87. 66   116. 69  
50-day avg:  21. 98   95. 54   123. 44  
200-day avg:  17. 74   94. 25   121. 11  
1-yr low:  10. 10   72. 78   98. 34  
volume:  74. 75 K 4. 11 M 8. 07 M
50-day avg volume:  525. 43 K 2. 76 M 5. 02 M
200-day avg volume:  230. 67 K 2. 92 M 4. 59 M

1-day return:  0. 04 % -0. 41 % 0. 07 %
this week return:  0. 04 % -5. 74 % -4. 11 %
12-wk return:  91. 09 % 1. 61 % -0. 05 %
52-wk return:  77. 82 % 3. 12 % 8. 78 %

enterprise value (EV):  689. 67 M 48. 94 B 114. 64 B
market cap:  855. 51 M 43. 07 B 104. 73 B
EBITDA:  -43. 88 M 4. 45 B 8. 01 B
enterprise multiple (EV/EBITDA):  -15. 72   4. 22   12. 73  
total debt:  0. 00   12. 24 B 16. 73 B
net income (common):  -36. 86 M 2. 20 B 4. 20 B

shares outstanding:  33. 54 M 571. 70 M 1. 24 B
shares:  1. 21 M 571. 81 M 1. 23 B
shares short:  86. 30 K 10. 17 M 13. 00 M
shares short prior month:  596. 32 K 9. 54 M 17. 33 M
short ratio:  0. 09   5. 41   3. 28  
total cash/share:  4. 90   11. 14   9. 33  
total cash:  164. 17 M 6. 71 B 7. 15 B
free cash flow:  -28. 29 M 3. 58 B 2. 96 B
operating cash flow:  -45. 63 M 4. 15 B 4. 30 B

book value:  4. 95   12. 78   26. 92  
price/book:  5. 16   3. 06   -1. 74  
operating margins:  0. 00 % -725. 35 % -89. 04 %
EBITDA margins:  0. 00 % 10. 94 % 22. 51 %
profit margins:  0. 00 % 7. 81 % 10. 57 %
gross margins:  0. 00 % 37. 08 % 55. 70 %

1-yr max volatility:  66. 09 % --- ---
1-yr mean volatility:  0. 38 % 0. 03 % 0. 04 %

1-yr EPS:  -1. 26   2. 40   4. 10  
forward EPS:  -1. 79   3. 97   7. 13  
P/E:  -20. 20   13. 63   22. 72  
forward P/E:  -14. 25   -15. 95   13. 99  
PE/G:  112. 89   -1. 65   -1. 32  
growth:  -0. 18 % 127. 12 % 29. 61 %
earnings high:  -0. 29   1. 00   1. 66  
earnings avg:  -0. 38   0. 77   1. 53  
earnings low:  -0. 50   0. 50   1. 39  
revenue high:  -0. 00   2. 68 B 10. 78 B
revenue avg:  -0. 00   2. 59 B 10. 57 B
revenue low:  -0. 00   2. 49 B 10. 36 B
return on assets:  -17. 51 % -2. 75 % 4. 55 %
return on equity:  -25. 30 % -18. 45 % 5. 46 %

beta (1yr vs S&P500):  0. 51   1. 25   0. 93  
sharpe (1yr):  1. 01   0. 37   0. 70  

held % insiders:  43. 12 % 6. 39 % 3. 38 %
held % institutions:  43. 67 % 78. 14 % 68. 52 %

Research more with google or yahoo!
the data below are updated and published after 9pm EDT each trading day

2019-04-21 : NITE
.    + 3.788 =         3.788 :: INITIAL WEIGHT
.   + 35.004 =        38.791 :: spline projection addition
.    x 1.431 =        55.527 :: industry recommendation factor
.    x 1.086 =        60.309 :: symbol recommendation factor
.    x 0.998 =        60.203 :: return on assets factor
.    x 0.997 =        60.051 :: return on equity factor
.    x 2.214 =       132.962 :: current ratio factor
.    x 1.044 =       138.833 :: quick ratio factor
.    x 2.197 =       304.946 :: short ratio factor
.    x 2.069 =       630.794 :: price-to-book factor
.    x 1.437 =       906.505 :: 5-day avg > 200-day avg
.     x 1.16 =      1051.354 :: 5-day avg > 50-day avg
.    x 1.239 =      1302.726 :: 50-day avg > 200-day avg
.    x 1.647 =      2145.568 :: P/E weight
.    x 0.307 =       658.236 :: PE/G factor
.    x 1.334 =       877.836 :: beta factor
.    x 1.005 =       882.337 :: sharpe factor
.    x 0.998 =        880.59 :: target low factor
.    x 1.049 =       923.691 :: target mean factor
.    x 1.042 =       962.443 :: target high factor
.     x 1.31 =      1260.692 :: industry 2-weeks return factor
.    x 0.776 =       978.299 :: overall "drift" factor
.    x 0.339 =       331.692 :: largest single-day jump factor
.     x 1.01 =       334.996 :: mean volatility factor
.    x 1.097 =       367.619 :: 42-day mean volatility factor
.      x 1.0 =        367.56 :: factor hist industry gain for week 16
.   cubeRoot =         7.163 :: reduced to standardize
.   - 20.782 =         0.482 :: add/subtract for performance
.                      0.482 :: FINAL WEIGHT for NASDAQ:NITE


 


News feed RSS items generated from finance.google.com

News feed formatting by feed2js.org